Abstract
Since the introduction of the first endovascular aneurysm sealing device (EVAS-1) by the Nellix System (Endologix, Inc, Irvine, CA), studies have demonstrated high reintervention and migration rates. However, prior reports showed higher 3-year survival compared with endovascular aneurysm repair (EVAR), which gave rise to interesting theories on the explanation of this observation. In this study, we examined 5-year all-cause mortality trends of EVAS-1 compared with EVAR.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
